使用脂质体纳米载体,改善了范科米辛衍生物FU002的药理动力学和提高了疗效
Julia Werner1, Florian Umstätter1, Tobias Hertlein2
1Heidelberg University Hospital, Department of Nuclear Medicine, Heidelberg, Germany.
Nanomedicine : nanotechnology, biology, and medicine
|December 29, 2023
概括
一种新型的万科米辛衍生物FU002显示出对抗耐药性格拉姆阳性细菌的强有力的活性. 在脂质体中封装FU002可以提高它的血液循环和治疗效果,而不会有毒.
科学领域:
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
- 药物运输 药物运输 药物运输
背景情况:
- 抗生素耐药性是全球主要的健康威胁,减少了有效的治疗选择.
- 范科米辛衍生物FU002对包括耐药菌株在内的グラム阳性细菌表现出高强度.
- FU002的快速消除限制了其临床应用.
研究的目的:
- 改善FU002.2的药理动力学概况.
- 评估脂质体FU002.2的安全性和有效性.
- 评估脂质体封装对FU002抗菌活性的影响.
主要方法:
- FU002被封装在PEGylated脂质体中.
- 细胞毒性测试是在肝脏,脏和红细胞上进行的.
- 在Wistar大鼠中进行了药理动力学研究.
- 使用微稀释试验对抗葡萄球菌和肠球菌的抗微生物活性进行了评估.
- 在Galleria mellonella幼虫感染模型中评估了治疗疗效.
主要成果:
- PEG-脂质体FU002没有显著的细胞毒性.
- 脂质体封装显著延长了FU002在老鼠的血液循环时间.
- 在封装后,对葡萄球菌和肠球菌的抗微生物活性保持不变.
- 在Galleria mellonella模型中,与自由FU002相比,脂质体FU002显示出更高的治疗效果.
结论:
- 脂质体封装是一种可行的策略,可以增强FU002的药理动力学.
- PEG-liposomal FU002是一种安全有效的配方,用于对抗阳性细菌感染.
- 这种方法有望克服抗生素耐药性并改善治疗结果.
相关概念视频
Factors Affecting Dissolution: Particle Size and Effective Surface Area
851
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
851
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
208
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
208


